Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer.

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer.

Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

Results: The numerous minimally invasive techniques that are available for the treatment of pilonidal disease have the advantages ... in patients with a pilonidal sinus larger than 4–5 cm ...

A Closer Look At These Complex Diseases Johnson & Johnson is the only pharmaceutical company investigating a treatment for three segments of debilitating auto- and alloantibody diseases ...

Anemia is common in CKD, especially in the later stages of the disease. You’re more likely to develop anemia if you also have diabetes or are on dialysis treatment. Tell your doctor if you ...

The newer therapies for myasthenia gravis, in their specificity, aim to provide disease modification. There is currently no cure for myasthenia gravis, but future targeted treatments may help more ...

Note: Alzheimer’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute ...

Huji Xu’s team was on tenterhooks after delivering the first treatments ... of a revolutionary cellular therapy for autoimmune diseases in September (X. Wang et al. Cell 187, 4890–4904 ...